U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07389577) titled 'A Study to Compare JL14002 to Lucentis(R) in Subjects With Wet Age-related Macular Degeneration (wAMD)' on Jan. 29.
Brief Summary: This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of JL14002 compared to Lucentis(R) in subjects with wAMD.
Study Start Date: March 01, 2022
Study Type: INTERVENTIONAL
Condition:
Wet Age-related Macular Degeneration
Intervention:
DRUG: JL14002 monoclonal antibody(Fixed dosing regimen)
For the first 12 weeks, a fixed dosing regimen will be administered, consisting of 0.5 mg JL14002 once every 4 weeks for a total of 3 consecutive doses.
DRUG: ...